Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Article

. 2017; 8(4): 112-116


Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative-Ischemic Conditions

Manoj Nepal, Suresh Jaisawal, Manish Guragain, Prakash Kafle, Satya Mukkera, Raj Kumar Ghimire, Beatty Simmonds, Usman M. Harris, Stanley Berger.

Abstract
Aims and Objectives: To find out if ischemia modified albumin can be a novel marker in ischemic heart disease. Materials
and methods: Retrospective chart-review of chest pain patients who were evaluated in the emergency departments
in 2006 and 2007. Results: Total of 400 patients presented with chest pain and subsequently were evaluated in the
Emergency department at two major emergency departments associated with the teaching hospital associated Mercy
Catholic Medical Center; few patients were excluded due to unavailability of complete data and follow-up visit in next
six months. Thus, finally 351 patients met criteria for final analysis. Primary endpoints included the cardiac events and
secondary outcomes were course in the hospital, days of hospitalization, interventions done in the hospital, disposition
from the hospital, and readmission within next six months. Sensitivity and specificity of ischemia modified albumin (IMA)
test was 80% and 50% respectively and positive predictive value and negative predictive values were 17% and 88%
respectively. There were no further differences in cardiac events or interventions in higher ischemia modified albumin
(IMA) group as compared to troponin (cTnT) (p=0.5). People with higher ischemia modified albumin (IMA) showed longer
hospitalization days (p=0.025), needing nursing home or skilled nursing facility on discharge due to high discharge needs
(p=0.0001) and had more readmissions as compared to troponin (p=0.02). However, Higher ischemia modified albumin
(IMA) did not predict more cardiovascular events during hospital stay, rather troponin (cTnT) test predicted arrhythmia
more than ischemia modified albumin (IMA) test (p=0.0001). Conclusion: Ischemia-modified albumin may be utilized
as a novel marker of ischemia to rule out acute coronary syndrome along with troponin and electrocardiogram in the
emergency departments. This test may also have short and long-term prognostic significances and may even be used as
a surrogate marker in stroke, sepsis and thrombo-embolic diseases once these people need admission to the hospital.

Key words: Acute Coronary Syndrome, Ischemia Modified Albumin, Ischemic Heart Disease, Prognosis.



Similar Articles

Exploring the Alzheimer's disease neuroepigenome: recent advances and future trends.
Zhang H, Elefant F
Neural regeneration research. 2022; 17(2): 325-327

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44

Differentiating Human Pluripotent Stem Cells to Vascular Endothelial Cells for Regenerative Medicine, Tissue Engineering, and Disease Modeling.
Bertucci T, Kakarla S, Kim D, Dai G
Methods in molecular biology (Clifton, N.J.). 2022; 2375(): 1-12

Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease.
Hernandez-Sapiens MA, Reza-Zaldívar EE, Márquez-Aguirre AL, Gómez-Pinedo U, Matias-Guiu J, Cevallos RR, Mateos-Díaz JC, Sánchez-González VJ, Canales-Aguirre AA
Neural regeneration research. 2022; 17(1): 31-37

A study of vegetable oil modified QCM sensor to detect β-pinene in Indian cardamom.
Debabhuti N, Mukherjee S, Neogi S, Sharma P, Sk UH, Maiti S, Sarkar MP, Tudu B, Bhattacharyya N, Bandyopadhyay R
Talanta. 2022; 236(): 122837


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.



ScopeMed Web Sites